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OBJECTIVES This study aimed to elucidate whether an antibody against oxidized low density lipoprotein
(anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression.
BACKGROUND It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with
atherosclerotic coronary artery disease.
METHODS In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we
performed quantitative coronary angiographic analysis of a lesion on a branch away from the
intervention site vessel and assessed lesion progression or regression using the Progression-
Regression score calculated as the baseline minimal lumen diameter minus the follow-up
minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-
linked immunosorbent assay method just before the initial angiography in all patients.
RESULTS The anti-Ox-LDL titer was 16.6 6 1.5 AcU/ml in the progression group (Progression-
Regression score .0.15 mm; n 5 20), which was significantly higher (p , 0.001) than the
value of 9.5 6 1.2 in the regression group (#20.15 mm; n 5 14) and also higher (p , 0.01)
than the value of 11.4 6 1.3 in the no-change group (20.15 to 0.15 mm; n 5 18). The
Progression-Regression score was correlated with the antibody titer in all patients (r 5 0.56,
p , 0.001). Multiple regression analysis showed that the Progression-Regression score was
independently correlated with the antibody titer (r 5 0.44, p , 0.01) as well as lipoprotein
(a) (r 5 0.33, p , 0.05).
CONCLUSIONS Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progres-
sion in the short term. (J Am Coll Cardiol 2001;37:1871–6) © 2001 by the American
College of Cardiology
Oxidized low density lipoprotein (LDL) is believed to play
a key role in the development of atherosclerosis (1). Oxida-
tive modification of LDL induces immunogenic epitopes in
the LDL molecule (2), and the presence of antibodies
against oxidized LDL (anti-Ox-LDL) has been demon-
strated in human sera (3,4). Several studies indicated that
higher levels of the anti-Ox-LDL titer were associated with
the presence of atherosclerotic disease (5–8). In other recent
studies, however, no such relationships between atheroscle-
rotic disease and the antibody titer have been found (9). On
the other hand, the anti-Ox-LDL titer has also been shown
to correlate with the rate of atherosclerosis progression, rather
than the presence of atherosclerosis itself (7). In this study, to
clarify these controversial results we angiographically assessed
lesion progression, or lesion regression of the coronary artery,
and investigated whether short-term coronary artery lesion
progression could be predicted by the anti-Ox-LDL titer.
METHODS
Patient selection. From patients with atherosclerotic cor-
onary artery disease undergoing elective coronary angio-
plasty for a single lesion and six-month follow-up coronary
angiography, we selected for this study 52 consecutive
patients (41 men and 11 women; age 63 6 1 year), who had
at least one lesion (25% to 75% diameter stenosis from a
visual impression) on the proximal portion of other major
branches besides the angioplasty site vessel. All patients had
received the standard medications for angina, including
nitrates, beta-blockers, calcium blockers and aspirin, which
were continued during the intervention procedure and not
changed until the follow-up angiography. Ticlopidine was
given if coronary stents were implanted in the intervention
site. Patients who received other cardioactive drugs includ-
ing angiotensin-converting enzyme inhibitors, patients who
had diabetes mellitus requiring oral hypoglycemic agents or
insulin injection, or patients who had other cardiac or
noncardiac complications that could have affected our anal-
ysis were also excluded. Each patient gave written informed
consent to participate in this study, which was approved by
the Dokkyo University Institutional Review Board and
conformed to the principles outlined in the Declaration of
Helsinki.
Angiographical assessment. We selected the most prox-
imal lesion from the lesions in the nonintervention
vessels as the target lesion for assessment of lesion
progression or regression during the six-month natural
course. If the lesions existed in both of two noninterven-
tion vessels, a lesion in the larger diameter vessel was
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nominated as the target lesion. On baseline coronary
angiography just before coronary angioplasty, all lesions
were visually assessed. In addition, the Gensini score,
which indicates the severity of the total lesions in the
entire coronary artery system, taking into consideration
both stenosis severity and lesion distribution, was calcu-
lated as described previously (10). Next, quantitative
coronary angiographic analysis of the target lesion was
performed twice (a baseline coronary angiography and
follow-up angiography) for assessment of lesion progres-
sion or regression. Quantitative coronary angiographic
analysis was performed on the same projection and the
minimal lumen diameter was measured. The progression
or regression of the lesion was evaluated using the
Progression-Regression score, calculated as the baseline
minimal lumen diameter minus the follow-up minimal
lumen diameter. The analyses were performed by one
investigator who was unaware of the identity of the
patient and the working hypothesis. Intraobserver vari-
ability for the measurement of the coronary artery diam-
eter showed high reproducibility (r 5 0.98, SEE 5 3.6%,
p , 0.001).
Assessment of coronary risk factors. Answers to questions
on history of hypertension, diabetes and smoking habits
were carefully noted for each patient. Blood pressure mea-
sured in the supine position in the morning on the day of
coronary angiography was evaluated. Mean blood pressure
was calculated as diastolic pressure plus one-third pulse
pressure. For the obesity index, the body mass index was
calculated as [weight/(height)2 kg/m2]. To evaluate smok-
ing habits, Brinkmann’s index was calculated as (cigarette
number 3 smoking year).
Lipid profile and glucose metabolism. Fasting venous
blood was collected from each patient early in the morning
on the day of coronary angioplasty and was used for routine
lipid profiling and glucose metabolism analysis. The residual
serum was frozen at 280°C until measurement of anti-Ox-
LDL. Serum total cholesterol and triglyceride levels were
determined by automated enzymatic assays (11,12). Low
density lipoprotein cholesterol was assayed from enzymatic
measurements and high density lipoprotein cholesterol was
determined using a precipitation method. Apolipoprotein
(apo) A-I, apo B and apo E were quantified with a
turbidimetric immunoassay. The assay method of lipopro-
tein (a) (Lp [a]) was a latex agglutination immunoassay. The
assay of remnant-like lipoprotein particle (RLP) cholesterol
was performed according to published methods (13,14)
using an RLP cholesterol assay kit. Plasma glucose was
determined by the glucose oxidase method and plasma
insulin level with a radioimmunoassay.
Assay of anti-Ox-LDL. The quantification of anti-Ox-
LDL was performed using an enzyme-linked immunosor-
bent assay (ELISA) kit (Ox-LDL IgG ELISA Test;
Biodesign International Inc., Saco, Maine), as reported
elsewhere (5–8). Briefly, serum was diluted 1:21 with a
sample diluent. Microtiter ELISA plates were precoated
with malonic dialdehyde (MDA)-induced Ox-LDL. One
hundred milliliters of the diluted specimen was added to
each well and incubated at 37°C for 30 min. After the wells
were washed five times, enzyme-labeled antihuman IgG was
added, followed by incubation at 37°C for 30 min. The wells
were again washed five times. Then, a substrate containing
p-nitrophenyl phosphate was added, with incubation at
37°C for 30 min. The reaction was stopped by 1.5 mol/L
sodium hydroxide. The absorbance was read at a wavelength
of 405 nm. In our laboratory, anti-Ox-LDL titer was 9.6 6
0.8 AcU/ml in 25 age-matched control subjects who un-
derwent diagnostic coronary angiography because they com-
plained of chest pain but had no detectable coronary artery
disease.
Statistical analysis. Data are expressed as mean 6 SE.
Comparisons among the three groups were performed with
one-way analysis of variance (ANOVA) followed by the
Student-Newman-Keuls test for multiple comparisons for
continuous variables, or Kruskal-Wallis ANOVA on ranks
followed by the Dann test for categorical variables. Corre-
lation of the Gensini score or the Progression-Regression
score with anti-Ox-LDL was assessed by a simple linear
regression. Multiple regression analysis was performed for
variables of the lipid profiles and anti-Ox-LDL predicting
the Progression-Regression score; p , 0.05 was considered
to be significant.
RESULTS
Lesion progression or regression during six-month
follow-up. Out of 52 study patients, the Progression-
Regression score was .0.15 mm in 20 patients (progression
group), $0.15 mm and .20.15 mm in 18 patients (no-
change group) and $20.15 mm in 14 patients (regression
group). Patient backgrounds and medications, including
lipid-lowering statins, were identical among the progression
group, the no-change group and the regression group
(Table 1). Table 2 shows a comparison of coronary risk
factors among the three groups. Significant differences were
observed in the fasting plasma insulin level and Lp(a), but
other coronary risk factors were identical in the three
groups.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ANOVA 5 analysis of variance
anti-Ox-LDL 5 antibody against oxidized low density
lipoprotein
apo 5 apolipoprotein
ELISA 5 enzyme-linked immunosorbent assay
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
MDA 5 malonic dialdehyde
RLP 5 remnant-like lipoprotein particle
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Anti-Ox-LDL and lesion progression. The anti-Ox-
LDL titer was 16.6 6 1.5 AcU/ml in the progression group,
which was significantly higher (p , 0.001) than the value of
9.5 6 1.2 in the regression group and also higher (p , 0.01)
than the value of 11.4 6 1.3 in the no-change group. There
was no significant difference in the anti-Ox-LDL titer
between the regression group and the no-change group
(Fig. 1). The Gensini score on baseline coronary angiogra-
phy was 53 6 4 in all patients. The anti-Ox-LDL titer did
not correlate with the Gensini score, but correlated with the
Progression-Regression score (r 5 0.56, p , 0.001) (Fig. 2).
Multiple regression analysis showed that the Progression-
Regression score was independently correlated with the
anti-Ox-LDL titer (r 5 0.53, p , 0.001) as well as Lp(a)
(r 5 0.38, p , 0.05). The most powerful predictor of
Progression-Regression score was the anti-Ox-LDL titer
(Table 3).
DISCUSSION
In the present study, we evaluated lesion progression or
regression during a relatively short term of six months
using a marker of Progression-Regression score assessed
by quantitative coronary angiographic analysis. The ma-
jor findings of our study are that the anti-Ox-LDL titer
was higher in the progression group than in the regres-
sion group and the no-change group, and that the
antibody titer correlated with the Progression-Regression
score. These results indicate that the anti-Ox-LDL titer
can predict lesion progression or regression over a six-
month period.
Immunologic response to oxidized LDL. Autoimmune
factors have been shown to play a dominant role in the
progression of atherosclerotic plaque (15). Autoantigens
that have been suggested to play a role in the autoimmune
process include oxidized LDL (16,17). Specific immuno-
logic epitopes expressed on oxidized LDL were found in
atherosclerotic lesions both in animals with experimental
atherosclerosis and in humans (3,18). T-cell-mediated im-
mune responses occur in such lesions. Thus, oxidized LDL
is an important local antigen in atherosclerosis and such
local T-cell responses may induce B-cell activation, with
concomitant systemic antibody production (19). Therefore,
anti-Ox-LDL can be considered a marker of LDL oxida-
tion at the tissue level on the vascular wall.
Table 1. Baseline Characteristics and Medication
Progression
Group (n 5 20)
No-Change
Group (n 5 18)
Regression
Group (n 5 14)
Age (yrs) 62 6 2 63 6 2 62 6 3
Gender (male/female) 15/5 15/3 11/3
Basal disease (AP/OMI) 12/8 10/8 7/7
Gensini score 50 6 6 47 6 6 65 6 12
Medication
Nitrates 18 (90%) 18 (100%) 13 (93%)
Calcium blockers 8 (40%) 5 (28%) 6 (43%)
Beta-blockers 3 (15%) 3 (17%) 2 (14%)
Aspirin 20 (100%) 17 (94%) 14 (100%)
Ticlopidine 10 (50%) 10 (56%) 8 (43%)
Lipid-lowering statins 3 (15%) 4 (29%) 2 (14%)
AP 5 angina pectoris; OMI 5 old myocardial infarction.
Table 2. Coronary Risk Factor Variables
Progression
Group (n 5 20)
No-Change
Group (n 5 18)
Regression
Group (n 5 14)
Body mass index (kg/m2) 24 6 1 24 6 1 25 6 1
Brinkmann’s index 572 6 58 662 6 52 576 6 66
Mean BP (mm Hg) 91 6 2 90 6 2 92 6 3
Fasting blood glucose (mg/dl) 102 6 4 99 6 4 95 6 5
Fasting plasma insulin (mU/l) 8.0 6 1.4* 5.0 6 0.5 3.5 6 0.5
Total cholesterol (mg/dl) 188 6 7 179 6 8 184 6 6
Triglyceride (mg/dl) 79 6 12 85 6 15 84 6 18
HDL cholesterol (mg/dl) 40 6 2 42 6 3 40 6 2
LDL cholesterol (mg/dl) 124 6 6 120 6 6 125 6 6
Apo A-1 (mg/dl) 109 6 4 106 6 6 106 6 4
Apo B (mg/dl) 104 6 4 99 6 4 103 6 3
Apo E (mg/dl) 3.5 6 0.2 3.2 6 0.2 3.4 6 0.3
Lp(a) (mg/dl) 33 6 4* 22 6 5 19 6 4
RLP cholesterol (mg/dl) 5.5 6 1.0 3.4 6 0.6 3.5 6 0.5
*p , 0.01 versus Regression Group.
Apo 5 apolipoprotein; BP 5 blood pressure; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; Lp(a) 5
lipoprotein(a); RLP 5 remnant-like lipoprotein particle.
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Anti-Ox-LDL as a marker of atherosclerotic coronary
artery disease. In previous reports, anti-Ox-LDL antibod-
ies have been shown to correlate with atherosclerotic coro-
nary (5,6), carotid (7) and peripheral artery disease (8). In
several other studies, however, no such relationships have
been found between atherosclerotic disease and the antibody
titer (9). This discrepancy may be because the importance of
anti-Ox-LDL responses varies depending on the stage of
atherosclerosis. On the other hand, Salonen et al. (7)
demonstrated, in a prospective ultrasound observation of
carotid atherosclerosis, that the anti-Ox-LDL titer was
correlated with the rate of lesion progression, but not with
baseline intima-media thickness. This fact suggests that the
anti-Ox-LDL titer may be a clinically useful marker for the
rate of lesion formation or disease activity, rather than a
marker for atherosclerosis severity. In the present study,
lesion progression or regression was evaluated via a six-
month follow-up. We speculate from our own study that
anti-Ox-LDL may be associated with relatively short-term
lesion progression.
We previously demonstrated that the anti-Ox-LDL titer
level was elevated in severe coronary artery disease but not in
mild coronary artery disease, using 126 consecutive patients
suspected of coronary artery disease who underwent diag-
nostic coronary angiography. We also showed that the titer
was higher in a subgroup of unstable angina than in other
groups. We concluded in these previous studies that the
anti-Ox-LDL titer level may be predictive of severe coro-
nary artery disease or of plaque instability (20). In the
present study, however, the anti-Ox-LDL titer did not
correlate with the baseline severity of coronary artery disease
assessed by the Gensini score. This was probably because
the patient population in the present study largely included
patients with relatively mild coronary artery disease. More
interestingly, in multiple regression analysis in the present
study, the anti-Ox-LDL titer independently correlated with
the Progression-Regression score but the serum LDL level
Figure 1. Comparison of the anti-Ox-LDL titer among the progression
group, the no-change group and the regression group. The titer was higher
in the progression group than in the regression group or the no-change
group. There was no significant difference in the antibody titer between the
regression group and the no-change group.
Figure 2. Correlation between the Gensini score and the antibody against oxidized low density lipoprotein (anti-Ox-LDL) titer (left) and between the
Progression-Regression score and the antibody titer (right). The anti-Ox-LDL titer did not correlate with the Gensini score, but correlated with the
Progression-Regression score.






Total cholesterol 0.021 0.949
Triglyceride 20.079 0.634
HDL cholesterol 20.006 0.971
LDL cholesterol 0.045 0.861
Lp(a) 0.376 0.032
RLP cholesterol 0.129 0.372
Anti-Ox-LDL 0.527 0.0002
Anti-Ox-LDL 5 antibody against oxidized low density lipoprotein. Other abbrevi-
ations as in Table 2.
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did not. This result indicates that the anti-Ox-LDL titer
can predict lesion progression independently of the serum
LDL level itself. In our results, Lp(a) was also higher in the
progression group than in the other group. In addition,
multiple regression analysis showed that Lp(a) correlated
with the Progression-Regression score. Lipoprotein(a),
which consists of LDL-like particles binding with apo B
and apo (a), is thought to inhibit the activity of the
fibrinolytic system and to be an independent coronary
risk factor (21). It has been reported that Lp(a) could
predict the severity and extension of coronary atheroscle-
rosis (22). Our results suggest that Lp(a) can also predict
short-term lesion progression. However, the predictive
ability of anti-Ox-LDL for lesion progression was higher
than that of Lp(a).
MDA-induced oxidation of LDL. In the present study,
we used a commercial kit for anti-Ox-LDL measurement.
In this assay, we measured the antibody against an epitope
of MDA-induced Ox-LDL. Recently, MDA-modified
LDL has been noticed because of its roles in the athero-
sclerotic process, and its plasma level is considered to be
associated with plaque inflammation or plaque instability
(23). In addition, the antibody against MDA-induced-Ox-
LDL was not only elevated in patients with acute myocar-
dial infarction (AMI) (24), but also could predict the
occurrence of AMI (5,25). These results suggest that
MDA-induced LDL oxidation may play an important role
in the development of plaque instability. The present study
indicates that MDA-induced LDL oxidation may also
affect the short-term progression of coronary atherosclerosis
and also suggests the importance of MDA-induced LDL
oxidation.
Study limitations. We evaluated lesion progression or
regression only by changes in the minimal lumen diameter,
using quantitative coronary angiographic analysis. Measure-
ment of the plaque area or plaque volume by intravascular
ultrasound would have provided more detailed informa-
tion about lesion progression or regression. Another
limitation is the possibility that medications continued
during the follow-up term, such as nitrates, beta-blockers,
calcium blockers, aspirin, ticlopidine or lipid-lowering
statins, affected lesion progression or regression. In our
study population, however, these medications were iden-
tical in all three groups: the progression, no-change and
regression groups.
Conclusions. The anti-Ox-LDL titer correlated with
short-term lesion progression or regression, rather than the
baseline severity of coronary artery disease. This antibody
titer may be an independent predictor of short-term lesion
progression.
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